This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week, we discuss the discovery that peritoneal membrane water transport, and PD outcomes, are influenced by genetic variations in the Aquaporin 1 channel.
When a study is negative the work is not done. Time to separate a negative trial from an underpowered one. Learn how to think about this with Manasi Bapat.
Timothy Yau teaches electrolyte free water. This is a concept that you will need to understand to get through next week's NephJC on sodium, water and the mission to Mars.